July 25, 2024 | Brainomix and Boehringer Ingelheim have entered a collaborative partnership for a program to improve the care of patients with fibrosing lung disease in the US; Durham University and Isfahan University of Medical Sciences have developed an innovative approach to diagnosing multiple sclerosis using advanced eye imaging techniques; and more.
Brainomix has entered a partnership with Boehringer Ingelheim for a collaborative program to improve the care of patients with fibrosing lung disease in the US. This project will focus on the opportunity for AI imaging analysis using Brainomix 360 e-Lung on routine CT scans to accelerate the diagnosis and improve access to treatment for people living with fibrosing lung disease. Through this partnership, Brainomix will deploy its FDA-cleared e-Lung software to leading US pulmonology centers and their networks of referring sites. The data generated will validate the value of e-Lung, highlighting the potential of digital technology to optimize pathways of care and improve outcomes for people with fibrosing lung disease. Press release.
Researchers at Durham University (Durham, UK) and Isfahan University of Medical Sciences (Isfahan, Iran) have developed an innovative approach to diagnosing multiple sclerosis using advanced eye imaging techniques. By training computer models to detect subtle changes in the eye, this method offers a faster, less invasive, and more accessible diagnosis method. The eye, being directly connected to the brain, can reveal early signs of neurological damage that might otherwise go unnoticed. Press release.
Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson’s disease based on the pace at which the disease progresses. In addition to having the potential to become an important diagnostic and prognostic tool, these subtypes are marked by distinct driver genes. If validated, these markers could also suggest ways the subtypes can be targeted with new and existing drugs. Press release.
Weill Cornell Medicine has also teamed up with Dana-Farber Cancer Institute to develop and test new artificial intelligence (AI) tools tailored to digital pathology—a relatively new field that uses high-resolution digital images that are created from tissue samples to diagnose diseases and inform treatment decisions. They found that ChatGPT can be tailored using an artificial intelligence technique called retrieval-augmented generation, to provide accurate responses to questions about digital pathology and compile detailed results. The authors also found that ChatGPT can help pathologists, without extensive coding experience, use complex software that analyzes tissue samples, effectively helping bridge the gap between pathology skills and digital pathology skills. Press release.
Heriot-Watt University and the Association of British HealthTech Industries (ABHI) are collaborating to increase the profile of Heriot-Watt as a hub of academic excellence. The collaboration will take a ‘triple helix’ approach, engaging academia, health systems, and industry partners throughout Scotland and the UK with a commitment to understanding the challenges innovators face in HealthTech research and commercialization, working to identify opportunities to overcome them through supported processes and policy lobbying. Press release.
Twist Bioscience has expanded its growing portfolio of synthetic viral controls with the launch of a synthetic RNA control for H5N1 Influenza A, which is one of the causes of Highly Pathogenic Avian Influenza (HPAI) or bird flu, covering 99.9% of hemagglutinin (HA) and neuraminidase (NA) genome regions. Positive controls provide quality control measures for the development, verification, and ongoing validation of both next-generation sequencing (NGS) and polymerase chain reaction (PCR) assays. The Twist control contains synthetic RNA segments of the complete H5N1 HA and NA genome regions, which determine the subtype of the strain. Press release.
Siemens Healthineers has added the NT-proBNPII (PBNPOO) assay to its comprehensive cardiac menu on the Atellica Solution to help diagnose heart failure. N-terminal proBNP (NT-proBNP) and Brain or B-type natriuretic peptides (BNP) are cardiac markers of stress that are released in response to increased ventricular filling pressure. The PBNPII assay from Siemens Healthineers supports timely patient care with a 10-minute time-to-first-result. Siemens Healthineers offers both natriuretic peptide tests to support choice and flexibility, as both assays can run on either the company’s Atellica IM or Atellica CI analyzer. Press release.
The University of Texas MD Anderson Cancer Center and Rice University announced the creation of the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis and treatment. Led by Rice’s Gang Bao, Ph.D., and MD Anderson’s Jeffrey Molldrem, M.D., the initiative aims to foster collaboration between the two institutions on fundamental and translational cancer research, to develop new technologies for cancer detection and therapy, and to secure external funding in support of further research and training. Press release.
AliveCor announced the U.S. Food & Drug Administration clearance and commercial launch of KAI 12L AI technology and the Kardia 12L ECG System. This is the world's first AI that can detect life-threatening cardiac conditions, including heart attacks, using a reduced leadset. The Kardia 12L ECG System is the world's first AI-powered handheld 12-lead electrocardiogram (ECG) system with a unique single-cable design. This AI technology can detect 35 cardiac determinations (14 arrhythmias and 21 morphologies), including serious conditions like acute myocardial infarction (MI) and the most common types of cardiac ischemia, using a reduced leadset. KAI 12L can seamlessly integrate with compatible devices, including the Kardia 12L ECG System, expanding critical access to accurate heart data within a broad range of healthcare settings. Press release.